Citations

Clear

3030 citation(s) found for "Susan, M".

Integrated transcriptomic analysis of human induced pluripotent stem cell-derived osteogenic differentiation reveals a regulatory role of KLF16
Ying, Ru , Ma, Meng , Kriti, Divya , Cohen, Ninette, D’Souza, Sunita L. , Schaniel, Christoph , Perrine, Susan M. Motch , Pichurin, Oksana , Pinto, Dalila , Holmes, Greg , Schadt, Eric E. , Bakel, Harm van , Ru, Ying, Zhou, Xianxiao , Kuo, Sharon , Housman, Genevieve , Zhang, Bin , Jabs, Ethylin W , Wu, Meng

Mayo Clinic

No container title available | May 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.106265.1 Get It

Abstract Osteogenic differentiation is essential for bone development, metabolism, and repair; however, the underlying regulatory relationships among genes remain poorly understood. To elucidate the transcriptomic changes and identify novel regulatory genes involved in osteogenic differentiation, we differentiated mesenchymal stem cells (MSCs) derived from 20 human iPSC lines into preosteoblasts (preOBs) and osteoblasts (OBs). We then performed transcriptome profiling of MSCs, preOBs and OBs. The iPSC-derived MSCs and OBs showed similar transcriptome profiles to those of primary human MSCs and OBs, respectively. Differential gene expression analysis revealed global changes in the transcriptomes from MSCs to preOBs, and then to OBs, including the differential expression of 840 genes encoding transcription factors (TFs). TF regulatory network analysis uncovered a network comprising 451 TFs, organized into five interactive modules. Multiscale embedded gene co-expression network analysis (MEGENA) identified gene co-expression modules and key network regulators (KNRs). From these analyses, KLF16 emerged as an important TF in osteogenic differentiation. We demonstrate that overexpression of Klf16 in vitro inhibited osteogenic differentiation and mineralization, while Klf16+/- mice exhibited increased bone mineral density, trabecular number, and cortical bone area. Our study underscores the complexity of osteogenic differentiation and identifies novel regulatory genes such as KLF16, which plays an inhibitory role in osteogenic differentiation both in vitro and in vivo.
Integrated transcriptomic analysis of human induced pluripotent stem cell-derived osteogenic differentiation reveals a regulatory role of KLF16
Ying, Ru , Ma, Meng , Cohen, Ninette, D’Souza, Sunita L. , Schaniel, Christoph , Perrine, Susan M. Motch , Pichurin, Oksana , Holmes, Greg , Schadt, Eric E. , Zhang, Bin , Ru, Ying, Zhou, Xianxiao , Kriti, Divya , Kuo, Sharon , Pinto, Dalila , Housman, Genevieve , Bakel, Harm van , Jabs, Ethylin W , Wu, Meng

Mayo Clinic

No container title available | May 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.106265 Get It

Abstract Osteogenic differentiation is essential for bone development, metabolism, and repair; however, the underlying regulatory relationships among genes remain poorly understood. To elucidate the transcriptomic changes and identify novel regulatory genes involved in osteogenic differentiation, we differentiated mesenchymal stem cells (MSCs) derived from 20 human iPSC lines into preosteoblasts (preOBs) and osteoblasts (OBs). We then performed transcriptome profiling of MSCs, preOBs and OBs. The iPSC-derived MSCs and OBs showed similar transcriptome profiles to those of primary human MSCs and OBs, respectively. Differential gene expression analysis revealed global changes in the transcriptomes from MSCs to preOBs, and then to OBs, including the differential expression of 840 genes encoding transcription factors (TFs). TF regulatory network analysis uncovered a network comprising 451 TFs, organized into five interactive modules. Multiscale embedded gene co-expression network analysis (MEGENA) identified gene co-expression modules and key network regulators (KNRs). From these analyses, KLF16 emerged as an important TF in osteogenic differentiation. We demonstrate that overexpression of Klf16 in vitro inhibited osteogenic differentiation and mineralization, while Klf16+/- mice exhibited increased bone mineral density, trabecular number, and cortical bone area. Our study underscores the complexity of osteogenic differentiation and identifies novel regulatory genes such as KLF16, which plays an inhibitory role in osteogenic differentiation both in vitro and in vivo.
A Novel Heterozygous Likely Pathogenic JAG1 Germline Variant in an Adult With Unilateral Persistent Fetal Vasculature
Olarewaju, Bukola A., Tejon, Judy B, Shen, Joanne F , Turkmani, Ali , Shen, Wei , Osundiji, Mayowa A. , Ellingson, Marissa Susan, Shen, Wei , Osundiji, Mayowa Azeez , Abbas, Mohammed Tiseer , Ellingson, Marissa S.

Mayo Clinic

American Journal of Medical Genetics Part A | May 27, 2025 | Volume: 197 | Issue: 9 | Pages: No page available

10.1002/ajmg.a.64098 | PMID 40259702 Get It

Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool
Hawkes, Will, Woodward, Gary , Hamza, Izhan, Desai, Viral , Barrett‐O’Keefe, Zachary , Grogan, Martha, Davison, Halley, Maurer, Mathew S. , Helmke, Stephen , Scherrer‐Crosbie, Marielle , Soltani, Marwa , Goyal, Akash , Zaręba, Karolina M. , Cheng, Richard K. , Vieira, Marcelo Luiz Campos , Elissamburu, Pablo , Ronderos, Ricardo , Prado, Aldo , Sarswat, Nitasha , Addetia, Karima , Ruberg, Frederick L. , Randazzo, Michael , Al-Roub, Nora , Kidd, Liam, Lang, Roberto M. , Pellikka, Patricia A. , Barrett-O'Keefe, Zachary, Scott, Christopher , Davison, Halley N, Cheng, Richard , Kirkpatrick, James N , Koutroumpakis, Efstratios , Deswal, Anita M , Pursnani, Amit , Pellikka, Patricia A , Slivnick, Jeremy A. , Hawkes, Will, OLIVEIRA, JORGE COELHO , Akerman, Ashley, Gómez, Alberto , Grogan, Martha , Dispenzieri, Angela , Scott, Christopher G. , Cotella, Juan Ignacio , Maurer, Mathew S , Kitano, Tetsuji , Takeuchi, Masaaki , Hotta, Viviane Tiemi , Patel, Amit R. , Asch, Federico M. , O’Driscoll, Jamie M. , Strom, Jordan B. , Kidd, Liam, Cuddy, Sarah A. M. , Upton, Ross

Mayo Clinic

European Heart Journal | May 26, 2025 | Volume: 46 | Issue: 40 | Pages: 4090-4101

10.1093/eurheartj/ehaf387 | PMID 40631729 Get It

Abstract Background and Aims Accurate differentiation of cardiac amyloidosis (CA) from phenotypic mimics remains challenging using current clinical and echocardiographic techniques. The accuracy of a novel artificial intelligence (AI) screening algorithm for echocardiography-based CA detection was assessed. Methods Utilizing a multisite, multiethnic dataset (n = 2612, 52% CA), a convolutional neural network was trained to differentiate CA from phenotypic controls using transthoracic apical four-chamber video clips. External validation was conducted globally across 18 sites including 597 CA cases and 2122 controls. Classification accuracy was assessed on the entire external validation dataset, and subgroup analyses were performed both on technetium pyrophosphate scintigraphy referrals, and individuals matched for age, sex, and wall thickness. Model accuracy was also compared with the transthyretin CA score and the increased wall thickness score within a subset of older heart failure with preserved ejection fraction patients with increased wall thickness. Results Cardiac amyloidosis patients and controls displayed similar age, sex, race, and comorbidities. After the removal of uncertain AI predictions (13%), model discrimination and classification were excellent for the entire external validation dataset [area under the receiver operating characteristic curve (AUROC) 0.93, sensitivity 85%, specificity 93%], irrespective of CA subtype (sensitivity: light-chain = 84%, wild-type transthyretin = 85%, and hereditary transthyretin = 86%). Performance was maintained in subgroup analysis in patients clinically referred for technetium pyrophosphate scintigraphy imaging (AUROC 0.86, sensitivity 77%, specificity 86%) and matched patients (AUROC 0.92, sensitivity 84%, specificity 91%). The AI model (AUROC 0.93) also outperformed transthyretin CA score (AUROC 0.73) and increased wall thickness (AUROC 0.80) scores. Conclusions This AI screening model—using only an apical four-chamber view—effectively differentiated CA from other causes of increased left ventricular wall thickness.
Impact of Marine Microplastics on Neurologic and Functional Disabilities: A Population‐Level Study
Makwana, Bhargav , Desai, Brinda, Srinivasan, Jayashri, Apetauerova, Diana, Sehgal, Siddharth, Yerstein, Oleg , Nasir, Khurram , Kong, Yixin , Rajagopalan, Sanjay , Al‐Kindi, Sadeer , Ganatra, Sarju , Ganatra, Sarju , Desai, Brinda, Dani, Sourbha S. , Khadke, Sumanth , Kumar, Ashish , Wadhera, Rishi K. , Navas‐Acién, Ana , Adamkiewicz, Gary , Moffatt‐Bruce, Susan D.

Mayo Clinic

European Journal of Neurology | May 21, 2025 | Volume: 32 | Issue: 5 | Pages: No page available

10.1111/ene.70144 | PMID 40396917 Get It

ABSTRACTBackgroundMicroplastics are emerging as environmental pollutants with potential neurotoxic effects, yet their association with neurological disabilities remains largely unexplored.MethodsIn this cross‐sectional study comprising 218 coastal counties in the United States, we compared the self‐reported prevalence of cognitive disability, mobility disability, self‐care disability, and independent living disability in counties with very high and low marine microplastic levels (MMLs). Unadjusted and adjusted prevalence ratios (PRs) were computed using population‐weighted quasi‐Poisson regression across three different models to examine the relationship between disability prevalence and MMLs.ResultsCounties exposed to very high marine microplastic levels had a higher mean prevalence of self‐reported cognitive disability (15.2% vs. 13.9%), mobility disability (14.1% vs. 12.3%), self‐care disability (4.2% vs. 3.6%), and independent living disability (8.5% vs. 7.7%) compared to those exposed to low levels (p < 0.001). Regression analyses revealed significantly elevated adjusted prevalence ratios (PRs) for cognitive (PR: 1.09 [95% CI: 1.06–1.12], p < 0.001), mobility (PR: 1.06 [1.03–1.10], p < 0.001), self‐care (PR: 1.16 [1.11–1.20], p < 0.001), and independent living disability (PR: 1.08 [1.05–1.12], p < 0.001) in counties with very high microplastic exposure compared to those with low exposure.ConclusionsThis study highlights a significant association between marine microplastic pollution and the self‐reported prevalence of cognitive, mobility, self‐care, and independent living disabilities at the county level. While merely associative, these findings emphasize the urgent need for further investigation into the individual‐level health impacts of microplastic exposure and underscore the importance of environmental interventions to mitigate potential risks.
Efficacy of pharmacological therapies in reducing outflow tract obstruction in patients with obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis
Couteur, David G. Le , Wilanksy, Susan, Lester, Steven J., Ommen, Steve R. , Geske, Jeffrey B. , Arsanjani, Reza, Ayoub, Chadi , Pereyra Pietri, Milagros, Pathangey, Girish , Le Couteur, David , Geske, Jeffrey B , Ayoub, Chadi , Awad, Kamal , Pereyra, Milagros , Farina, Juan M. , Abbas, Mohammed Tiseer , Scalia, Isabel G. , Arsanjani, Reza

Mayo Clinic

European Heart Journal - Cardiovascular Pharmacotherapy | May 16, 2025 | Volume: 11 | Issue: 5 | Pages: 469-482

10.1093/ehjcvp/pvaf036 | PMID 40377024 Get It

Abstract Aims Significant advancements have been made in the management of obstructive hypertrophic cardiomyopathy (oHCM), yet the extent of left ventricular outflow tract (LVOT) gradient reduction achieved with commonly used pharmacological therapies [beta-blockers (BBs), calcium channel blockers (CCBs), disopyramide, and cardiac myosin inhibitors (CMIs)] relative to each other is still unclear. Methods and results PubMed and Scopus were searched up to September 2024. Clinical trials or observational studies that assessed the changes associated with BBs, CCBs, disopyramide, or CMIs in LVOT gradient at rest or with provocation in patients with oHCM were included. Mean changes in LVOT gradients were pooled as mean differences (MD) with 95% confidence intervals (CIs) in a random-effects model. Thirty-seven studies, with 44 arms and 1898 patients, were included in the analysis. At the therapeutic class level, pooled analysis showed that disopyramide was associated with the highest reduction in LVOT gradient at rest [MD: −43.5 (95% CI, −51.6 to −35.3)], followed by CMIs [MD: −34.8 (95% CI, −40.6 to −29.0)], BBs [MD: −20.7 (95% CI, −29.4 to −12.0)], and then CCBs [MD: −14.7 (95% CI, −23.3 to −6.1)], inter-action P &lt; 0.01. Within CMIs, mavacamten had a higher effect than aficamten on gradient reduction; among the included BBs, metoprolol showed the highest gradient reduction, while among CCBs, verapamil was the most effective (inter-action P &lt; 0.01). Similar results were observed for provocable LVOT gradients. Conclusion Pharmacological therapies effectively reduced LVOT gradients in oHCM patients to varying degrees, with disopyramide and CMIs showing the highest effect, followed by BBs and CCBs.
Genotype–phenotype correlations and clinical outcomes of genetic TRPC6 podocytopathies
McAnallen, Susan, Elhassan, Elhussein A. , Stoneman, Sinéad, Hogan, Marie C. , Hoefele, Julia , Clince, Michelle , Jorge, Sofía , Calado, Joaquim , Colliou, Éloïse, Tellier, Stéphanie , Cornet, Joséphine, Fallois, Jonathan de , Dossier, Claire , Loberti, Lorenzo , Godefroid, Nathalie, Astrid, Dubrasquet, Kálmán, Tory, Dolan, Niamh, Alawi, B, Sweeney, Clodagh, Stack, Maria, Awan, Atif , Hui, Ng Kar, Harris, Trudie , Haeberle, Stefanie , Schäfer, Franz, McCann, Emma, Vairo, Filippo , Hogan, Marie C , Hoefele, Julia , Titan, Silvia M , Renieri, Alessandra , Pinto, Anna Maria , Quintana, Luis F , Becherucci, Francesca , Biros, Erik , Kidd, Kendrah , Mallett, Andrew J , Vairo, Filippo Pinto e , Mekraksakit, Poemlarp , Titan, Silvia , Decramer, Stéphane , Francisco, Telma , Servais, Aude , Fenoglio, Roberta , Renieri, Alessandra , Daga, Sergio , Fila, Marc , Quintana, Luís F. , Godefroid, Nathalie, Kálmán, Tory, Dolan, Niamh, Alawi, Bushra Al, Riordan, Michael , McCarthy, Hugh J. , Bleyer, Anthony J. , Sayer, John A , Benson, Katherine Angela , Conlon, Peter J.

Mayo Clinic

Nephrology Dialysis Transplantation | May 15, 2025 | Volume: 41 | Issue: 1 | Pages: 79-91

10.1093/ndt/gfaf086 | PMID 40388293 Get It

ABSTRACT Background and hypothesis Podocytopathy associated with likely pathogenic/pathogenic variants of Transient receptor potential cation channel subfamily C member 6 (TRPC6) (TRPC6-AP) has been recognized for about 20 years. As a result of its rarity however, the spectrum of clinical phenotypes and genotype–phenotype correlation of TRPC6-AP remains poorly understood. Here, we characterized clinical, histological and genetic correlates of familial and sporadic patients with TRPC6-AP. Methods In this multicentre observational study, an online questionnaire followed by a systematic literature review was performed to create a cohort with comprehensive data on genetic and clinical outcomes [age of onset, clinical presentation, treatment response, kidney biopsy findings and progression to kidney failure (KF)]. Logistic regression, Cox proportional hazards model and Kaplan–Meier analyses investigated the associations between genetic variants and disease progression. Results Among 87 families (96 familial and 45 sporadic cases), 31 distinct missense TRPC6 variants (including 2 novel) were identified, with c.2683C&gt;T p.(Arg895Cys) and c.523C&gt;T p.(Arg175Trp) the commonest variants. Proteinuric kidney disease/nephrotic syndrome was the most common clinical presentation (83.7%), while focal segmental glomerulosclerosis was the most common histological finding (89.4%). By 33 (interquartile range 17–40) years, 48.9% (69/141) of patients had progressed to KF. Sporadic TRPC6-AP demonstrated an earlier progression to KF than familial cases (P = .001) and were more likely to present with nephrotic syndrome [odds ratio 4.34 (1.85–10.15); P = .001]. Gain-of-function TRPC6 variants were more frequent in familial than sporadic TRPC6-AP (70.8% vs 44.4%; P = .004). Compared with patients with other TRPC6 variants, patients with TRPC6 p.R175W and p.R895C variants progressed to KF earlier [median kidney survival of 21 years, hazard ratio 2.985 (95% confidence interval 1.40–5.79); and 38 years, hazard ratio 1.65 (95% confidence interval 1.01–2.81), respectively, log-rank P = .005]. Conclusion Our study shows unique clinical and genetic correlations of TRPC6-AP, which may enable personalized care and promising novel therapies.
From embedded interprofessional clinics to expanded alcohol-associated liver disease programs
Winder, Gerald Scott , Banerjee, Arpita Goswami, Bryce, Kelly , Fipps, David C. , Hussain, Filza, Omary, Lesley, Patel, Shivali , Rubman, Susan , Shenoy, Akhil , Suzuki, Joji , Zimbrean, Paula C. , Brown, Kimberly , Mellinger, Jessica L. , Hussain, Filza , Im, Gene , Patel, Arpan , Serper, Marina , Shenoy, Akhil , Suzuki, Joji , Abouljoud, Marwan , Mellinger, Jessica , Winder, Scott , Fipps, David C , Arab, Juan Pablo , Patel, Arpan , Serper, Marina

Mayo Clinic

Liver Transplantation | May 13, 2025 | Volume: 31 | Issue: 12 | Pages: 1567-1580

10.1097/lvt.0000000000000638 | PMID 40359009 Get It

Hazardous alcohol use remains a major contributor to acute and chronic liver disease, while alcohol-associated liver disease (ALD) is a leading indication for liver transplantation. In recent years, embedded, interprofessional ALD clinics have improved access to alcohol use disorder care within hepatology and liver transplantation, but more work is needed to meet this challenge. The literature is lacking regarding scaling procedures to provide services for increasingly large ill patient populations. This article begins to fill this gap by describing “expanded ALD care”: broad, innovative, longitudinal, interprofessional care delivery strategies surpassing standalone clinics. Drawing from analogous patient populations served by collaborative models in primary care and comprehensive eating disorder treatment, the expanded ALD care framework proposes practical strategies toward specific innovations: equipoise between biomedical and psychosocial care elements, increased clinician number and reach, long-term patient relationships, harm reduction and palliative care, outreach to external agencies and clinicians, and enhanced support for patients and families. The article also defines attributes of innovative healthcare systems that support expanded ALD care.
Diagnosis of Sub-centimeter Nodules Through Shape-sensing Robotic Assisted Bronchoscopy: Real-world Outcomes from the Ion Registry
Pritchett, M., Garwood, Susan, Jiwani, Alisha, Abedi, Ali , Bawaadam, Hasnain , Icard, Bradley , Revelo, Alberto , Reisenauer, Janani , Oh, Saecheol , Postigo, M., Garwood, S., Peralta, A.R.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A2720-A2720

10.1164/ajrccm.2025.211.abstracts.a2720 Get It

Abstract RATIONALE: As technology for biopsy of peripheral pulmonary nodules advances, the size of suspicious nodules referred for biopsy has decreased. This can be partly attributed to tools such as shape-sensing robotic-assisted bronchoscopy (ssRAB), which can increase the likelihood of a diagnostic result. Literature describing the biopsy of sub-centimeter nodules is primarily single center with a reported diagnostic yield for robotic bronchoscopy of 67%1, and 71%2 for CT-guided percutaneous biopsy; robust prospective multi-center data is needed to further understand the feasibility and clinical value of &lt;1cm nodule biopsies. Herein, we report data from the prospective Ion Registry describing outcomes for patients with sub-centimeter nodules biopsied using ssRAB. METHODS: Patients with at least one (1) nodule &lt;1cm that underwent ssRAB biopsy were identified from those enrolled in the Ion Registry. Subjects with multiple lesions were included if all nodules were &lt;1cm in largest diameter. Nodule and procedure characteristics are reported with descriptive statistics; diagnostic yield was assessed using the ATS/ACCP recommended guidelines of index biopsy results only. Safety was assessed as the rate of pneumothorax requiring intervention and Nashville Grade ≥3 bleeding. RESULTS: Fifty-four (54) subjects and 57 sub-centimeter nodules were identified across 9 centers and 15 investigators; procedures were completed October 2023 through September 2024. The majority of nodules (47.4%) were incidental findings. Median nodule diameter was 8 mm (IQR: 7,9; range: 4.0-9.7 mm) with 66.7% of nodules located in the outer-third of the lung, and predominantly (57.9%) in the upper lobes. CT bronchus sign was present in 24.6% of nodules, and most (89.5%) nodule were solid. Median procedure time was 34.5 mins (IQR: 26,47; range: 9-89 mins); fixed or mobile CBCT was utilized for 80.7% (46/57) of nodules. The flexision biopsy needle and cryoprobe were used in 91% and 49% of biopsies, respectively. Diagnostic yield was 83% (45/54) using index biopsy results, 59% of which were malignant. No (0%) pneumothorax requiring intervention, Nashville Grade ≥3 bleeding events. CONCLUSION: Preliminary results from this prospective, multi-center registry cohort demonstrate peripheral nodules &lt;1cm can be safely and effectively diagnosed through ssRAB biopsy and highlight the impact of ssRAB in enhancing lung nodule diagnosis, particularly when combined with CBCT. These findings suggest ssRAB may be considered a viable option for the biopsy of suspicious sub-centimeter nodules, further optimizing the management of patients with suspected lung cancer. REFERENCES:1. 10.1016/j.chest.2021.07.2169 2. https://doi.org/10.1016/j.clinimag.2020.04.040
Global research aims for the study of cost and value in health professions education: A Delphi study of international experts
Tolsgaard, Martin G. , Nayahangan, Leizl Joy , Cook, David A. , Schalkwyk, Susan van , You, You , van Schalkwyk, Susan , You, Michelle You , Cleland, J , Tolsgaard, Martin , Madsen, Gorm Roager , Brydges, Ryan , Filho, Carvalho , Cleland, Jennifer

Mayo Clinic

Medical Teacher | May 10, 2025 | Volume: 47 | Issue: 11 | Pages: 1752-1760

10.1080/0142159x.2025.2501254 | PMID 40347090 Get It